Kangmei Pharmaceutical Co Ltd (600518) — Cash Flow-to-Debt Ratio
Kangmei Pharmaceutical Co Ltd (600518) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of CN¥219.96 Million could theoretically repay 0% of its total liabilities (CN¥6.46 Billion) in one year. See how financially flexible is Kangmei Pharmaceutical Co Ltd to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kangmei Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (1999–2024)
Historical debt coverage capacity for Kangmei Pharmaceutical Co Ltd across 26 annual periods. For the full cash flow conversion analysis, see Kangmei Pharmaceutical Co Ltd operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Kangmei Pharmaceutical Co Ltd (1999–2024)
Year-by-year debt coverage analysis for Kangmei Pharmaceutical Co Ltd. Check Kangmei Pharmaceutical Co Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.06x | CN¥-427.63 Million | CN¥6.59 Billion | ▼ -47.2% |
| 2023 | -0.04x | CN¥-317.52 Million | CN¥7.20 Billion | ▲ +51.9% |
| 2022 | -0.09x | CN¥-749.96 Million | CN¥8.18 Billion | ▼ -360.3% |
| 2021 | 0.04x | CN¥214.21 Million | CN¥6.09 Billion | ▲ +49.3% |
| 2020 | 0.02x | CN¥1.03 Billion | CN¥43.74 Billion | ▼ -64.0% |
| 2019 | 0.07x | CN¥2.88 Billion | CN¥43.94 Billion | ▲ +909.4% |
| 2018 | 0.01x | CN¥305.62 Million | CN¥47.03 Billion | ▲ +104.9% |
| 2017 | -0.13x | CN¥-4.84 Billion | CN¥36.78 Billion | ▼ -308.8% |
| 2016 | 0.06x | CN¥1.60 Billion | CN¥25.44 Billion | ▲ +138.6% |
| 2015 | 0.03x | CN¥508.86 Million | CN¥19.27 Billion | ▼ -74.0% |
| 2014 | 0.10x | CN¥1.13 Billion | CN¥11.16 Billion | ▼ -38.1% |
| 2013 | 0.16x | CN¥1.67 Billion | CN¥10.22 Billion | ▲ +19.8% |
| 2012 | 0.14x | CN¥1.01 Billion | CN¥7.38 Billion | ▲ +42.4% |
| 2011 | 0.10x | CN¥574.96 Million | CN¥5.99 Billion | ▼ -52.9% |
| 2010 | 0.20x | CN¥669.19 Million | CN¥3.28 Billion | ▲ +231.9% |
| 2009 | 0.06x | CN¥119.47 Million | CN¥1.95 Billion | ▲ +2532.9% |
| 2008 | 0.00x | CN¥3.02 Million | CN¥1.29 Billion | ▼ -98.7% |
| 2007 | 0.18x | CN¥162.55 Million | CN¥882.71 Million | ▲ +106.6% |
| 2006 | 0.09x | CN¥68.32 Million | CN¥766.30 Million | ▼ -85.5% |
| 2005 | 0.62x | CN¥133.13 Million | CN¥216.45 Million | ▲ +168.0% |
| 2004 | 0.23x | CN¥78.52 Million | CN¥342.09 Million | ▼ -22.8% |
| 2003 | 0.30x | CN¥78.02 Million | CN¥262.25 Million | ▲ +32.6% |
| 2002 | 0.22x | CN¥53.47 Million | CN¥238.35 Million | ▲ +118.1% |
| 2001 | 0.10x | CN¥15.69 Million | CN¥152.51 Million | ▲ +31.4% |
| 2000 | 0.08x | CN¥9.96 Million | CN¥127.27 Million | ▼ -70.0% |
| 1999 | 0.26x | CN¥30.25 Million | CN¥115.77 Million | — |